A Phase 3 interventional study of Acetaminophen 650 mg/Naproxen Sodium 220 mg and Placebo tablet in Fever, sponsored by Kenvue Brands LLC. Recruiting at 1 site in United States. Open to male participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-19.
Sponsored by Kenvue Brands LLC · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 118 studies in Fever with a site in United States — 14 open to participants now, 15 under way, 1 of them phase 3. Fever · United States.
Among the 118 studies in Fever with a site in United States, this one is the 18th largest by planned enrollment of the 84 interventional ones that give a count, is one of 3 that started in 2026, is one of 25 in phase 3, reaches primary completion later than 10 of the 12 other live ones, and was the 117th registered.
439 studies on the registry are indexed under Fever; 55 are open to participants now.
Browse Fever studies →14 of the 118 studies in Fever with a site in United States are open now. Recruiting first, the newest first:
Vanderbilt University Medical Center · Sites in United States
Ages 1 days–12 mo
Duke University · Sites in United States
Ages 6 wk–30 wk · Healthy volunteers
All Natural Medicine Clinic, LLC · Sites in United States
University of Texas at Austin · Sites in United States
Ages 6 mo–36 mo
University of Miami · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 38 Fever studies recruiting now, 18 (47%) set no upper age limit and 14 (37%) stop at 75 or younger; 22 take children under 18; 11 take healthy volunteers.
This study: 18 Years to 55 Years · male · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
118 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 12 · Phase 3 25 · Phase 4 11
First in 1978; this study’s year is marked. 3 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 292 is above the median of 123 across 271 interventional studies indexed under Fever.
Median enrollment 102 across the 84 interventional studies, 315 across the 29 observational. Of the 91 that completed or were terminated, 44 (48%) have results posted.
This tab as a report to print or save as PDF → With an account.
47 of 118 have an industry lead sponsor. The 10 most frequent:
Kenvue Brands LLC is the lead sponsor of 9 studies on the registry; 3 are open to participants now.
Kenvue Brands LLC has 1 study filed under Fever — fewer than ten, so there is no comparison to draw.
6 of the studies in Fever with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07948811Phase 3Kenvue Brands LLCA Study Evaluating the Antipyretic Efficacy and Safety of an Acetaminophen/Naproxen Sodium Fixed Combination in Subjects With Endotoxin-Induced Fever | 2027-10-29 |
| NCT04790240All Natural Medicine Clinic, LLCMedical Herbs Inhibit Inflammation Directing T Cells to Kill the COVID-19 Virus (COVID) | 2026-12-30 |
| NCT05952999OSF Healthcare SystemAnalysis of the Virtual Acute Care at Home Experience | 2026-12-31 |
| NCT07158814Duke UniversitySafety of RSV Preventive Monoclonal Antibody | 2027-02 |
| NCT04669886University of MiamiSerum Endotoxin Assay to Predict the Development of Postoperative Infectious Complications and Systemic Inflammatory Response Following Percutaneous Nephrolithotomy. | 2027-03-30 |
Add all 6 to your calendar (.ics) → With an account.
Among the 118 studies in Fever with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
To evaluate the antipyretic efficacy of a single dose of a fixed combination of acetaminophen/naproxen sodium, compared with placebo.
This will be a randomized, single-dose, double-blind, placebo-controlled, parallel-group study to evaluate the antipyretic efficacy and safety of a fixed-dose combination (FDC) of acetaminophen/naproxen sodium in adult subjects with endotoxin-induced fever, compared to placebo.
The study will be conducted in two study phases (Phase A and Phase B), with the intent of Phase A being for endotoxin dose evaluation and the intent of Phase B being to evaluate the investigational product (IP)/placebo.
Subjects enrolled in Phase A will not be included in Phase B, nor will data from these subjects be included in the statistical analysis. Phase A will be completed prior to starting Phase B. Data from Phase A will be reviewed by the Phase A Data Review Team to determine if a satisfactory endotoxin dosing regimen has been achieved. Once a satisfactory dosing regimen is determined, separate subjects will be enrolled in Phase B. Once the endotoxin induced qualifying fever (temperature ≥38.1°C) is established, eligible subjects will be randomized in a 1:1 allocation to receive a single dose of either the IP or the placebo
Inclusion Criteria
Subjects must meet all of the following inclusion criteria in Sections A and B to be eligible for enrollment into the study:
A) Assessed at Screening Visit (Visit 1):
B) Assessed at Day 0 and Day 1 (of Visit 2):
C) Assessed Once Qualifying Fever Established (Randomization Criteria; Phase B Only) Subjects must meet all of the following criteria following endotoxin administration in order to be randomized during Phase B. Subjects who do not meet these criteria will not be randomized.
Exclusion Criteria (to be assessed at Visit 1, Day 0 of Visit 2, and Day 1 of Visit 2).
Subjects must not meet any of the following exclusion criteria to be eligible for enrollment into the study
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Acetaminophen 650 mg/Naproxen Sodium 220 mg (administered as two tablets of Acetaminophen/Naproxen Sodium 325 mg/110 mg).
Drug: Acetaminophen 650 mg/Naproxen Sodium 220 mg
Placebo (administered as two tablets of placebo).
Drug: Placebo tablet
The IP is to be taken as a single dose (administered as two tablets of Acetaminophen/Naproxen Sodium 325 mg/110 mg) orally with 180 mL of room temperature water.
The placebo is to be taken as a single dose (administered as two tablets of placebo) orally with 180 mL of room temperature water.
Time-weighted Sum of Temperature Differences (WSTD) from 0 to 8 hours (WSTD 0-8)
WSTD 0-8 was defined as time-weighted sum of temperature differences over 8 hours, weighted by time elapsed between each 2 consecutive time points post treatment (5,10, 15,20,25,30,35,40,45,50, 55,60,70,80, 90,100, 110,120,150,180,210,240,270,300,330,360,390,420,450, and 480 minutes after the investigational study material (ISM) administration (Hour 0). Temperature difference was defined as baseline temperature (at Hour 0) minus the post-baseline temperature at each time point up to 8 hours (5,10, 15,20,25,30,35,40,45,50, 55,60,70,80, 90,100, 110 minutes,2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, and 8 hours).
Time frame: Baseline (0 hour) up to 8 hours
Time-weighted Sum of Temperature Differences (WSTD) from 0 to 12 hours (WSTD 0-12)
WSTD 0-12 was defined as time-weighted sum of temperature differences over 8 hours, weighted by time elapsed between each 2 consecutive time points post treatment (5,10, 15,20,25,30,35,40,45,50, 55,60,70,80,90,100,110,120,150,180,210,240,270,300,330,360,390,420,450, 480,510,540,570,600,630,660,690,and 720 minutes after the investigational study material (ISM) administration (Hour 0). Temperature difference was defined as baseline temperature (at Hour 0) minus the post-baseline temperature at each time point up to 12 hours (5,10, 15,20,25,30,35,40,45,50, 55,60,70,80, 90,100, 110 minutes,2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5, 9, 9.5, 10, 10.5, 11, 11.5 , and 12 hours).
Time frame: Baseline (0 hour) up to 12 hours
Time-weighted Sum of Temperature Differences (WSTD) from 0 to 6 hours (WSTD 0-6)
WSTD 0-6 was defined as time-weighted sum of temperature differences over 8 hours, weighted by time elapsed between each 2 consecutive time points post treatment (5,10, 15,20,25,30,35,40,45,50, 55,60,70,80, 90,100, 110,120,150,180,210,240,270,300,330, and 360 minutes after the investigational study material (ISM) administration (Hour 0). Temperature difference was defined as baseline temperature (at Hour 0) minus the post-baseline temperature at each time point up to 6 hours (5,10, 15,20,25,30,35,40,45,50, 55,60,70,80, 90,100, 110 minutes,2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, and 6 hours).
Time frame: Baseline (0 hour) up to 6 hours
Time-weighted Sum of Temperature Differences (WSTD) from 0 to 10 hours (WSTD 0-10)
WSTD 0-10 was defined as time-weighted sum of temperature differences over 8 hours, weighted by time elapsed between each 2 consecutive time points post treatment (5,10, 15,20,25,30,35,40,45,50, 55,60,70,80,90,100,110,120,150,180,210,240,270,300,330,360,390,420,450, 480,510,540,570, and 600 minutes after the investigational study material (ISM) administration (Hour 0). Temperature difference was defined as baseline temperature (at Hour 0) minus the post-baseline temperature at each time point up to 10 hours (5,10, 15,20,25,30,35,40,45,50, 55,60,70,80, 90,100, 110 minutes,2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5, 9, 9.5, and 10 hours).
Time frame: Baseline (0 hour) up to 10 hours
Subject Global Evaluation Questionnaire
Participants will be asked to evaluate the performance of the investigational study material (ISM) using a 5-point Likert scale : 0= poor , 1=fair , 2=good , 3=very good , 4=excellent
Time frame: Visit 2 - 12 hours prior to first use of rescue medication, or at time of early discontinuation (whichever occurs first).
Time to first use of rescue medication
Time to rescue medication (other than study treatment) was defined as time from first dosing of study medication to the time a participant first takes a rescue medication, or to the end of the study time for participants that do not take any rescue medication prior to the end of the study. The rescue medication was defined as medication received for the treatment of fever during the time period from the administration of study medication to the time of end of the study.
Time frame: Baseline (0 hour) to 12 hours
Proportion of subjects using rescue medication from 0 to 12 hours
Time frame: Baseline (0 hour) to 12 hours
Started Oct 2026 (actual). Primary completion is estimated for Oct 2027, 12 months after the start.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Kenvue Brands LLC